This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Alemtuzumab is an anti-CD52 monoclonal antibody indicated for the treatment of relapsing-remitting multiple sclerosis (RRMS) with high disease activity despite previous disease-modifying therapies.1 It is administered by IV infusion in a first cycle of 12 mg/d for 5 days (60 mg) and in a second cycle of 12 mg/d for 3 days (36 mg) after 12 months from the first cycle. The most common infusion-associated reaction (IAR), occurring in 90% of alemtuzumab-treated patients, is cytokine-release syndrome, which is managed by premedicating with steroids and treating with symptomatic therapy. Incidence of cardiac-related IARs is 13% (tachycardia, bradycardia, palpitations), of which only 0.7% are serious cardiac-related IARs such as atrial fibrillation, sinus bradycardia, sinus tachycardia, hypotension, or hypertension, and all these events are most frequent on the first day of infusion.2
Footnotes
↵* These authors contributed equally to this work.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Editorial, page 819
See page 827
See page 849
- Received September 17, 2017.
- Accepted in final form January 19, 2018.
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.